Dr. William Degrado Honored With The Ralph F. Hirschmann Award In Peptide Chemistry

Dr. William DeGrado, the scientific
founder of PolyMedix, Inc. (OTC BB: PYMX, polymedix), was
named the 2008 recipient of the prestigious Ralph F. Hirschmann Award
in Peptide Chemistry. The award recognizes a person who has made
outstanding contributions in the chemistry, biochemistry, or
biophysics of peptides.


Dr. DeGrado is the scientific founder of and Chief Scientific Advisor
for PolyMedix, an emerging biotechnology company developing new
therapeutic drugs for serious, life-threatening acute cardiovascular
and infectious disease. He is a Professor of Biochemistry and
Biophysics at the University of Pennsylvania School of Medicine in
Philadelphia, PA, and a member of the National Academy of Sciences.
He is a former President of the Protein Society, has over twenty
issued U.S. patents, and has over two hundred publications to his name.


Dr. DeGrado's work laid the foundations for PolyMedix's core lead
drug development programs and product candidates. Both PMX-30063
antibiotic, the world's first small molecule mimetic of host defense
proteins intended for systemic use, and PMX-60056 heptagonist, a new
reversing agent for heparin and Low Molecular Weight Heparins, are
based on pioneering discoveries originally made by Dr. DeGrado.


The Ralph F. Hirschmann Award was established by The Merck Research
Laboratories in 1988. This award, administered by the American
Chemical Society (ACS) was presented to Dr. DeGrado at the awards
ceremony on Tuesday, April 8, 2008, in conjunction with the 235th ACS
national meeting in New Orleans, LA.


"It is a great privilege and honor to work with such a renowned
scientist as Dr. DeGrado. PolyMedix has been able to achieve great
things because we have had the good fortune of building on the
pioneering breakthroughs of Dr. DeGrado. We look forward to
continuing to work together with him in the development of important
new medicines," commented Nicholas Landekic, President & Chief
Executive Officer of PolyMedix.


About PolyMedix, Inc


PolyMedix is a publicly traded biotechnology company focused on the
development of novel drugs and biomaterials for the treatment of
infectious diseases and acute cardiovascular disorders. PolyMedix's
compounds are based on biomimetics: non-peptide small molecule drugs
that mimic the activity of proteins. The Company's antibiotic
compounds - small molecule mimetics of human host-defense proteins -
are believed to have a completely different mechanism of action from
all current antibiotic drugs, a mechanism which is intended to make
bacterial resistance unlikely to develop. These compounds are being
developed as rapidly acting antibiotics for serious systemic and
local infections. The Company is also developing polymeric
formulations as antimicrobial biomaterials, which can be used as
additives to paints, plastics, and textiles to create self-
sterilizing products and surfaces. The Company's heptagonist
compounds reverse the activity of both heparin and low molecular
weight heparins, in keeping with our goal of developing an antagonist
drug that is safer and easier to use than currently approved therapy.
PolyMedix plans to shortly file regulatory applications in
anticipation of commencing human clinical trials for both its
antibiotic and heptagonist compounds. For more information, please
visit PolyMedix on its website at polymedix.















This press release contains forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 that involve risks and that could cause
PolyMedix's actual results and experience to differ materially from
anticipated results and expectations expressed in these forward
looking statements. PolyMedix has tried, wherever possible, to
identify these forward-looking statements by using words such as
"anticipates," "believes," "hopes," "estimates," "looks," "expects,"
"plans," "intends" and similar expressions. Among other things, there
can be no assurance that PolyMedix's compounds will enter or
successfully complete clinical testing or be granted regulatory
approval to be sold and marketed in the Unites States or elsewhere. A
more complete description of these risks, uncertainties and
assumptions is included in PolyMedix's filings with the Securities
and Exchange Commission. You should not place undue reliance on any
forward-looking statements. PolyMedix undertakes no obligation to
release publicly the results of any revisions to any such forward-
looking statements that may be made to reflect events or
circumstances after the date of this press release or to reflect the
occurrence of unanticipated events.

polymedix